Guardant Health, Inc. Chief People Officer Terilyn J. Monroe filed a Form 4 on November 19, 2026, disclosing the sale of 3,842 shares of common stock on November 18, 2026, pursuant to a Rule 10b5-1 trading plan.

Key Highlights

  • Reporting person: Terilyn J. Monroe, Chief People Officer of Guardant Health, Inc. (NASDAQ:GH)
  • Total shares sold: 3,842 shares of common stock disposed of on November 18, 2026
  • Price range: Sales occurred across five tranches at weighted average prices ranging from $140.64 to $144.58 per share
  • Remaining holdings: Monroe beneficially owned 21,058 shares directly following the reported transactions
  • 10b5-1 plan: The filing indicates transactions were made pursuant to a contract, instruction, or written plan satisfying the affirmative defense conditions of Rule 10b5-1(c)
  • Transaction code: All five transactions were coded "S" (open-market sale), all direct ownership

Monroe's Five-Tranche Sale of Guardant Health Common Stock

According to the Form 4 filing, Terilyn J. Monroe, serving as Chief People Officer of Guardant Health, Inc., sold a combined 3,842 shares of the company's common stock on November 18, 2026. The sales were executed in five separate tranches. The first tranche disposed of 500 shares at a weighted average price of $140.64, with individual transaction prices ranging from $140.335 to $140.890. The second tranche covered 1,200 shares at a weighted average of $141.7888, with prices from $141.385 to $142.310.

The filing further discloses that 1,338 shares were sold at a weighted average of $142.8291, with prices ranging from $142.41 to $143.19, and 704 shares were sold at a weighted average of $143.6356, with prices from $143.420 to $144.115. A fifth and final tranche of 100 shares was sold at $144.58. The filing notes that for each weighted-average tranche, Monroe "has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range."

Following all reported transactions, Monroe's direct beneficial ownership stood at 21,058 shares of common stock, according to the filing. The form was signed by John G. Saia as attorney-in-fact for Terilyn J. Monroe and was filed on November 19, 2026. All transactions were classified as direct ownership with no derivative securities reported in Table II.

What Was Disclosed

Guardant Health Chief People Officer Terilyn J. Monroe disclosed the sale of 3,842 shares of common stock on November 18, 2026, across five tranches at weighted average prices between $140.64 and $144.58, under a Rule 10b5-1 plan, leaving her with 21,058 shares directly held.